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Abstract 
Background: Hyperlipidemia is a major component of metabolic syndrome, and often predicts cardiovascular 
diseases. We developed a new therapeutic agent berberine compounds (BC), consisting of berberine, oryzanol and 
vitamin B6, and determined their anti-hyperlipidemia activity and underlying mechanisms.
Methods: Male Wistar rats were fed a high fat diet (HFD) to induce hyperlipidemia, and then given BC orally for 
4 weeks. Body weight and food intake were recorded weekly, and lipid profiles in serum were determined biochemi-
cally. Metabolites in serum, urine, liver and feces were analyzed by GC–MS, and the structure of microbiota was deter-
mined by 16S rDNA sequencing.
Results: Lipid lowering was observed in the hyperlipidemic rats upon BC treatment without apparent adverse side 
effects. Metabolomics analysis indicated that the BC treatment resulted in increased pyruvic acid, serotonin, and 
ketogenic and glycogenic amino acid levels in the serum, increased pyridoxine and 4-pyridoxic acid in the urine, 
decreased hypotaurine and methionine in the liver, and increased putrescine and decreased deoxycholate and litho-
cholate in feces. The BC treatment also resulted in an enrichment of beneficial bacteria (e.g. Bacteroides, Blautia) and a 
decrease in Escherichia.
Conclusions: The lipid lowering effect of BC treatment in hyperlipidemic rats is associated with a global change in 
the metabolism of lipids, carbohydrates and amino acids, as well as the structure of microbiota.
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Background
Hyperlipidemia is a consternation of several plasma lipo-
protein abnormalities, including increased triglyceride 
(TG) and/or total cholesterol (TC), low-density lipo-
protein cholesterol (LDL-c), and decreased high-density 
lipoprotein cholesterol (HDL-c) in serum [1]. Regarded 
as a modifiable risk factor for metabolic diseases includ-
ing nonalcoholic fatty liver disease, type 2 diabetes 
mellitus and cardiovascular disease [2, 3], hyperlipidemia 
is becoming an important public health concern with 
increased incidence and prevalence [1]. Commonly used 
medications for hyperlipidemia include statins, fibrates, 
bile acid sequestrants, nicotinic acid, and cholesterol 
absorption inhibitors [4]. Unfortunately, many medica-
tions have significant adverse effects, such as statin myo-
pathy, liver injury, and sleep disturbance [5]. Hence, new 
drugs of effectiveness and safety remain to be explored.
Some natural products that been used in traditional 
Chinese medicine show remarkable anti-hyperlipi-
demia efficacies. For instance, the alkaloid berberine 
(BBR), a quaternary ammonium salt isolated from Rhi-




*Correspondence:  jiliver@vip.sina.com 
1 Institute of Digestive Diseases, China-Canada Center of Research 
for Digestive Diseases (ccCRDD), Longhua Hospital, Shanghai University 
of Traditional Chinese Medicine, Shanghai 200032, China
Full list of author information is available at the end of the article
Page 2 of 13Li et al. J Transl Med  (2016) 14:237 
anti-microbial medicine, possesses an anti-hyperlipi-
demic potential [7, 8]. Both pre-clinical and clinical stud-
ies have demonstrated beneficial effects of BBR in the 
management of hyperlipidemia [9, 10]. However, the 
low intestinal bioavailability of BBR [11], demands a 
high dose and/or long-term treatment, which often elicit 
unwanted side effects (e.g. constipation, nausea, and 
abdominal distension) [12].
We have developed a new agent, designated BBR com-
pounds (BC), consisting of BBR, oryzanol and vitamin 
B6. Oryzanol is a particular bioactive compound found in 
rice bran that has been shown to exert an effect on lipid 
metabolism [13–15]. Vitamin B6 is a co-enzyme that par-
ticipates in various metabolic activities [16]. In addition, 
oryzanol and vitamin B6 appear to exert an effect on met-
abolic pathways that are shared with BBR [14–16].
In this study, we first examined the effect of BC in alle-
viating hyperlipidemia using a diet-induced rat model, 
and determined metabolome using gas chromatography/
mass spectrometry (GC/MS)-based approach [17–20]. 
Because gut microbiota play a critical role in modulating 
metabolism and drug bioavailability [21–23], the effect of 




BBR, γ-oryzanol, pyridoxine (vitamin B6), urease, 
pyridine, methoxylamine hydrochloride, L-phenyla-
lanine-13C9-15N, dulcitol, L-leucine-13C6, L-isoleucine-
13C6-15N, L-valine-13C5-15N, L-alanine-13C3-15N and 
N,O-bis(trimethylsilyl)-trifluoroacetamide (BSTFA) with 
1 % trimethylchlorosflane (TMCS) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Pure water was 
obtained from Millipore Alpha-Q water system (Bed-
ford, MA, USA). Methanol and ethanol for HPLC grade 
were purchased from Merck Chemicals (Darmstadt, 
Germany). Chloroform for analytical grade from Sinop-
harm Chemical Reagent Company (Shanghai, China). 
KAPA HiFi polymerase (KAPA Biosystems, USA), Agen-
court AMPure XP beads (Beckman Coulter, USA), Qubit 
dsDNA HS assay kit (Invitrogen, CA), Agilent high sen-
sitivity DNA Kit (Agilent, USA), Ion PGM template OT2 
200 kit, Ion PGM sequencing 200 kit v2 and Ion 316 chip 
kit v2 (Life Technology, CA) and QIAamp® Fast DNA 
stool mini kit (Qiagen, Germany) were obtain for fecal 
microbiota analysis.
Animal study
Male Wistar rats (8-week old, weighting 180–220 g), pur-
chased from Shanghai SLAC Laboratory Animal Co., 
Ltd (Shanghai, China), were housed in a standard 12  h 
light/12 h dark cycle. The animal room temperature and 
relative humidity were 22 ± 2  °C and 60 ± 5 %, respec-
tively. After 1-week acclimatization, rats were divided 
into chow diet group (n = 10) and HFD (10 % lard, 20 % 
sucrose, 2 % cholesterol, 1 % bile salt and 67 % standard 
chow) group (n = 20). Blood samples were collected ran-
domly from tail vein of 6 rats in each group after 4 week 
feeding, and TC, TG, LDL-c, HDL-c and free fatty acid 
(FFA) level in serum were quantified. The hyperlipi-
demic rats were further divided into two groups, namely, 
untreated group (continued to supply HFD, n  =  10) 
and BC treated group (with HFD and BC supplementa-
tion, n = 10). BC (150 mg/kg of BBR, 24 mg/kg of ory-
zanol and 10 mg/kg of vitamin B6) were suspended with 
0.5  % sodium carboxy methylcellulose (CMC-Na) solu-
tion, and then administered by oral gavage for the next 
4 weeks. The chow diet and HFD groups (untreated) rats 
were received an equal volume 0.5 % CMC-Na solution. 
Food intake and body weight were recorded weekly. At 
the end of experiment, all rats were fasted overnight, 
and sacrificed with 2  % sodium pentobarbital anesthe-
sia (0.5 mL/100 g). Blood samples were drawn from the 
abdominal aorta, and the serum was obtained by cen-
trifugation at 3000  rpm for 15  min at 4  °C. To collect 
urine and feces samples, six rats in each experimental 
group were housed in metabolic cages, and the samples 
accumulated in the metabolic cages were immediately 
transferred into sterile tubes. The liver samples were 
immediately dissected, weighted, washed with icy normal 
saline, snap-frozen in liquid nitrogen, and then stored at 
−80 °C.
All the experimental protocols were approved by the 
animal committee of Shanghai University of Traditional 
Chinese Medicine.
Biochemical analysis of serum
The levels of TC, TG, LDL-c, HDL-c, FFA, total bilirubin 
(TBIL), total bile acids (TBA) and alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) 
enzymes in serum, were determined by an automatic bio-
chemical analyzer. SPSS 17.0 statistical software (SPSS, 
Chicago, IL, USA) was used for data analysis. Statistical 
analysis was carried out using one-way analysis of vari-
ance (ANOVA). The criterion used for statistical signifi-
cance was p < 0.05.
Sample preparation for GC–MS
For each serum sample (20 μL), 80 μL of ice-cold metha-
nol containing 10 μL of internal standards (0.02 mg/mL 
of L-phenylalanine-13C9-15N, 0.05  mg/mL of dulcitol, 
L-leucine-13C6 and L-isoleucine-13C6-15N, 0.1  mg/mL of 
L-valine-13C5-15N and L-alanine-13C3-15N) was added. 
For each urine sample (15  μL), 15  μL urease solution 
were blended and catalyzed at 37 °C for 60 min, and then 
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180  μL of ice-cold ethanol containing 10  μL of internal 
standards (0.05 mg/mL of L-phenylalanine- 13C9-15N and 
dulcitol) was added. For each liver tissue or feces sample 
(40 ± 5 mg), 800 μL chloroform/methanol/water (v/v/v, 
2:5:2 in ice water) mixture were added and homogenized. 
After centrifuged at 16,000g for 15  min, the superna-
tant (100 μL) was added to a GC vial, containing 10 μL 
of internal standards (0.05  mg/mL of L-phenylalanine-
13C9-15N and dulcitol).
The respective serum, urine, liver and feces samples 
were dried under gentle nitrogen stream. The glass vial 
with dry residue was added with 30  μL of 20  mg/mL 
methoxylamine hydrochloride in anhydrous pyridine. 
The resultant mixture was vortex-mixed vigorously for 
30 s and incubated (37 °C for 90 min). A 30 μL of BSTFA 
(with 1 % TMCS) was added into the mixture and deri-
vatized (70 °C for 60 min).
GC/MS analysis
Each derivatized sample (1  μL) was injected using the 
splitless mode with an Agilent Technologies 7890A 
chromatograph equipped with a HP-5MS column 
(30  m  ×  0.25  mm  ×  0.25  μm) and Agilent Technolo-
gies 5975C inert MSD detector. The initial oven tem-
perature was held at 70 °C for 2 min, increased to 160 °C 
with 6  °C/min, and then to 240  °C with 10  °C/min, and 
finally increase to 300  °C with 20  °C/min, constant for 
6 min, with He as carrier gas (1 mL/min) and MS detec-
tion. The temperatures of injector, transfer line, and elec-
tron impact ion source were set to 250, 290, and 230 °C, 
respectively.
Data processing and multivariate data analysis by GC/MS
The extraction, alignment, deconvolution, and further 
processing of raw GC/MS data were converted into 
NetCDF format via DataBridge (Perkin-Elmer, USA). The 
data was normalized against total peak intensities before 
performing univariate and multivariate statistics. Multi-
variate data analysis was carried out using SIMCA-P 11.0 
software (Umetrics AB, Umeå, Sweden) to perform prin-
cipal component analysis (PCA) where general clusters 
and outliers were observed. Prior to PCA, all data were 
mean-centered and unit variance-scaled. Subsequently, 
the data were subjected to partial least squares-discri-
minant analysis (PLS-DA) and orthogonal partial least 
squares-discriminant analysis (OPLS-DA) where a model 
was built and utilized to identify and reveal differential 
metabolites accountable for the separation between iden-
tified groups. The differential metabolites were deter-
mined by cross-referencing with the Golm Metabolome 
Database. In addition, metabolic pathway interpreta-
tion of differential metabolites was performed using the 
KEGG database.
Fecal DNA extraction and pyrosequencing
For the extraction of fecal DNA, 180–220 mg each stool 
sample were weighed on ice and operated based on the 
protocol for “Isolation of DNA from stool for human 
DNA analysis” in the handbook provided by QIAamp 
DNA stool mini kit. DNA yields are determined from the 
concentration of DNA in the eluate, measured by absorb-
ance at 260 nm. Purity is determined by calculating the 
ratio of absorbance at 260 to 280 nm, measured by Nan-
oDrop microvolume quantitation of nucleic acids. pure 
DNA has an A260/A280 ratio of 1.7–1.9.
The DNA extractive from each stool sample was 
used as a template for the amplification of V3 region 
of 16S rDNA genes. The bacterial genomic DNA was 
PCR amplified with the forward primers (5′-TCGTCG-
G C A G C G TC A G ATG TG TATA A G A G A C A G C -
CTACGGGNGGCWGCAG) and the reverse primers 
(5 ′-GTCTCGTGGGCTCGGAGATGTGTATAAG 
AGACAGGACTACHVGGGTATCTAATCC) for the V3 
hypervariable regions of the 16S rDNA gene.
The PCR condition were 95  °C for 3 min, followed by 
25 cycles of 95  °C for 30 s, 55  °C for 30 s and 72  °C for 
30 s, and then 72 °C for 5 min on an Eppendorf thermo-
cycler. The PCR products were verified on a Bioanalyzer 
DNA 1000 chip (Agilent), and the expected size on a Bio-
analyzer trace after the Amplicon PCR step is ~550  bp. 
Then we use AMPure XP beads to purify the 16S V3 
amplicon away from free primers and primer dimer spe-
cies, and quantified the sample with fluorometric quan-
tification method that used dsDNA binding dyes. The 
concentrated final library was diluted to 4  nM using 
resuspension buffer (RSB) or 10  mM Tris pH 8.5. 5 μL 
of diluted DNA from each library was mixed for pooling 
libraries with unique indices. After samples were loaded, 
the MiSeq system provided instrument secondary analy-
sis using the MiSeq Reporter software (MSR). The MSR 
provided several options for analyzing MiSeq sequencing 
data. All operations for fecal microbe analysis were per-
formed under sterile conditions.
Bioinformatics and statistical analysis
Raw pyrosequencing reads generated from the sequencer 
were quality filtered by FASTX Toolkit 0.0.13 (http://
hannonlab.cshl.edu/fastx_toolkit/index.html). The high-
quality valid reads were clustered into operational taxo-
nomic units (OTUs) using Mothur (http://www.mothur.
org/). The representative sequences of OTUs were 
used to analyze α-diversity (rarefaction curve analysis 
and Shannon diversity index) on the basis of their rela-
tive abundance. A heatmap was generated according to 
the relative abundance of OTUs by R software (http://
www.R-project.org). Phylogenetic β-diversity measures 
such as unweighted unifrac significance test, principal 
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coordinate analysis (PCoA) and nonmetric multidimen-
sional scaling (NMDS) were performed using representa-
tive sequences of OTUs for each sample by the Mothur 
program to analyze community and phylogenesis. Tax-
onomy-based analyses were performed to classify taxo-
nomically using the ribosomal database project (RDP) 
classifier with a 60 % bootstrap score.
Results
The effect of BC treatment on diet‑induced hyperlipidemia 
in rats
Male Wistar rats developed hyperlipidemia after 5 weeks 
of HFD feeding. Thus, the serum TC and LDL-c concen-
trations were increased whereas HDL-c concentration 
decreased as compared to chow diet controls (Addi-
tional file 1: Figure S1). A trend of increase in serum TG 
and FFA was also observed in HFD-fed group, although 
the difference was statistically insignificant. Treatment 
of the hyperlipidemic rats with BC for 4  weeks signifi-
cantly attenuated the serum concentrations of TG, TC, 
LDL-c, whereas the serum HDL-c concentration was 
restored as compared to that in untreated (i.e. HFD 
alone) rats (Fig. 1a–d). The serum FFA concentration was 
unchanged (Fig. 1e).
The effect of BC treatment on body and liver weight
Rats fed HFD for 9  weeks developed hepatomegaly 
(Table 1). The body weight between HFD-fed and chow 
diet-fed rats showed no difference (Table 1). After 4-week 
BC treatment, both body weight and liver/body weight 
ratio were decreased compared with those untreated 
(i.e. HFD alone) rats (Table 1). Food intake was identical 
between HFD and BC-treated groups (Table 1), thus the 
weight loss upon BC treatment was unrelated to satiety.
The effect of BC treatment on serum metabolites
Analysis of serum metabolites between HFD-fed (i.e. 
hyperlipidemia model) and chow diet-fed rats revealed 
changes in 31 serum metabolites (Additional file 1: Table 
S1). Of which, metabolites related to fatty acid synthesis 
or cholesterol synthesis were enhanced, whereas metab-
olites related to TCA cycle were decreased (Additional 
file 1: Table S1) upon high fat dieting.
We next determined the effect of BC treatment on 
serum metabolites in the hyperlipidemic rats. The R2X 
and Q2 of PCA score analysis were 0.595 and 0.101, 
respectively; the R2Y and Q2 of PLS-DA score analysis 
were 0.995 and 0.802, respectively. These data indicated 
the validity of current models.
Distinct clustering of serum metabolites was appar-
ent between control and BC treated groups (Fig.  2a, b). 
The set of identified metabolites were systematically 
searched for Pearson’s correlations, and the correlations 
were indicated in different colors (Fig.  2c). Fold change 
(FC) of each metabolite was used to construct a heat 
map (Fig.  2d). Compared with the metabolic profiles of 
untreated rats, 15 metabolites were increased and 16 
decreased in BC treated rats, and the profiles are sum-
marized in Fig.  2e. Among the increased metabolites, 
oxaloacetic acid, pyruvic acid and malic acid are involved 
in glycolysis and the TCA cycle (Fig.  2f ), glutamic acid, 
aspartic acid, and alanine are involved in the metabo-
lism of gluconeogenic amino acids (i.e. alanine, aspartate 
and glutamate) (Fig. 2g). Decreased metabolites, such as 
cis-11,14-eicosadienoic acid, stearic acid, margaric acid, 
myristic acid, arachidic acid, trans-oleic acid, palmitoleic 
acid, and palmitic acid, are involved in fatty acid biosyn-
thesis (Fig. 2h).
The effect of BC treatment on urine metabolites
A total of 51 urine metabolites showed difference 
between HFD-fed and chow diet-fed rats (Additional 
file 1: Table S2), of which 15 were increased and 41 were 
decreased. Alterations in these metabolites suggested 
suppression in the TCA cycle, the pentose phosphate 
pathway, and purine/pyrimidine metabolism (Additional 
file 1: Table S2).
We next determined the effect of BC treatment on 
urine metabolites in the hyperlipidemic rats. The R2X and 
Q2 of PCA score analysis were 0.557 and 0.204, respec-
tively; the R2Y and Q2 of OPLS-DA score analysis were 
0.995 and 0.824, respectively (Fig.  3a, b), indicating the 
classifications was well suited for the models, and the 
BC untreated and treated groups were classified clearly. 
The set of identified metabolites was systematically 
searched through for Pearson’s correlations (Fig.  3c), 
and FC of each metabolite was used to construct a heat 
map (Fig.  3d). The observed changes in metabolites 
in the rat urine samples were summarized in Fig.  3e. 
Notably, metabolites pyridoxine and 4-pyridoxic acid 
that are related to vitamin B6 metabolism were remark-
ably increased (Fig. 3f ) upon BC treatment. In addition, 
metabolites involved in phenylalanine metabolism, such 
as succinic acid and 3-hydroxyphenylpropionic acid, 
were decreased, whereas phenylacetic acid and phenyl-
lactic acid were increased (Fig. 3g).
The effect of BC treatment on liver metabolites
For liver samples, we identified 36 metabolites in hyper-
lipidemic rats that distinctly different from those in chow 
diet group (Additional file  1: Table S3), 16 metabolites 
were increased and 20 metabolites were decreased in 
hyperlipidemic rats. These altered metabolites were sup-
posed to be involved in the TCA cycle, the pentose phos-
phate pathway, fatty acid metabolism, and amino acid 
metabolism (Additional file 1: Table S3).
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We next determined the effect of BC treatment on liver 
metabolites in the hyperlipidemic rats. The R2X and Q2 
of PCA score analysis were 0.539 and 0.226, respectively; 
the R2Y and Q2 of OPLS-DA score analysis were 0.996 
and 0.564, respectively (Fig. 4a, b), validating the classifi-
cation for the chosen model. The set of identified metab-
olites was systematically searched through for Pearson’s 
correlations (Fig. 4c), and FC of each metabolite was used 
to construct a heat map (Fig.  4d). Metabolites from the 
BC treated liver samples that were significantly differ-
ent are summarized in Fig.  4e. Glucuronic acid, lyxonic 
acid, 3-hydroxyadipic acid and galacturonic acid showed 
increase, whereas phytosterol, γ-aminobutyric acid, 
methionine, nonanoic acid, hypotaurine, 1-octadecanol, 
lyxosylamine and N-acetylgalactosamine were decreased 
(Fig. 4f ).
The effect of BC treatment on fecal metabolites
For the fecal samples, 27 metabolites were up-regulated 
and 16 metabolites were down-regulated in hyperlipi-
demic rats (Additional file 1: Table S4). Changes in these 
metabolites suggested the enhancement in fatty acid and 
Fig. 1 Changes of serum parameters in rats. Male Wistar rats (8 weeks of age) placed on HFD or chow diet for 8 weeks, HFD rats were divided into 
BC treated and untreated groups, with the 4-week intervention. At the end of experiment, blood was collected, and serum was separated, the lipid 
profiles were analyzed. a TC, b LDL-c, c HDL-c, d TG, e FFA. The data were presented as the mean ± SD. ***P < 0.001, compared with chow group; 
#P < 0.05, ##P < 0.01 and ###P < 0.001, compared with untreated (HFD) group
Table 1 Phenotypic parameters
Data are presented as mean ± SD
***P < 0.001, compared with chow diet group; #P < 0.05, compared with HFD group
Items Chow diet rats (n = 10) HFD rats (n = 10) BC treated rats (n = 10)
Body weight (g)-initial 199.43 ± 8.99 204.49 ± 11.33 204.38 ± 13.48
Body weight (g)-final 362.75 ± 22.33 382.71 ± 18.19 356.05 ± 19.72#
Liver weight (g) 9.44 ± 1.63 15.10 ± 1.00*** 13.50 ± 1.20***
Liver/body weight ratio (%) 2.59 ± 0.36 3.93 ± 0.28*** 3.80 ± 0.32***
Daily food intake (g/rat) 20.74 ± 2.01 13.93 ± 2.06*** 14.70 ± 3.13***
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cholesterol synthesis, and the suppression in TCA cycle, 
tryptophan metabolism, and purine/pyrimidine metabo-
lism (Additional file 1: Table S4).
We next determined the effect of BC treatment on fecal 
metabolites in the hyperlipidemic rats. The R2X and Q2 
of PCA score analysis were 0.548 and 0.262, respectively; 
the R2Y and Q2 of PLS-DA score analysis were 0.989 and 
0.912, respectively (Fig. 5a, b), indicating the classification 
was well suited for the models, and the profiles between 
BC treated rats and hyperlipidemic rats were classified 
clearly. The set of identified metabolites was systemati-
cally searched through for Pearson’s correlations (Fig. 5c). 
FC of each metabolite was used to construct a heat map 
(Fig. 5d). The observed changes in endogenous metabo-
lites in rat feces were summarized in Fig. 5e. It was noted 
that the BC increased the metabolites (tyrosine, hydro-
caffeic acid, 4-hydroxycinnamic acid and indole-3-lactic 
acid) involved in the tyrosine metabolism (Fig.  5f ), the 
metabolites (pantothenic acid, γ-aminobutyric acid and 
β-alanine) involved in the β-Alanine metabolism (Fig. 5g) 
and the metabolites (ornithine, proline and putrescine) 
involved in the arginine and proline metabolism (Fig. 5h), 
and decreased the metabolites (deoxycholate and litho-
cholate) involved in the secondary bile acid biosynthesis 
(Fig. 5i).
The effect of BC treatment on the structure of microbiota 
in feces
We used high quality pyrosequencing technology to 
determine the structure of fecal microbiota. A total 
of 363,615 usable raw sequences (average of 20,201 
sequences per sample) and 34,866 operational tax-
onomic units (OTUs) were generated by pyrose-
quencing method from 18 samples. Rarefaction and 
Shannon diversity curves demonstrated that most of 
the diversity had already been captured (Additional 
Fig. 2 The metabolic profiles in the serum. The HFD induced hyperlipidemic rats were treated with or without BC for 4-week, serum was collected, 
and metabolomics analysis was made by GC/MS. a PCA score plots serum samples from BC treated group and untreated group; b scores plots of 
PLS-DA between untreated group and BC treated group; c Pearson’s correlations of the quantities of the 35 metabolites determined from serum 
samples; d heat map showing the fold change (FC) of 19 metabolites. Shades of green represent FC decrease while red represent FC increase; e 
simplified draft illustrating perturbed pathways involved; f differential metabolites between the groups in glycolysis and citrate cycle; g differential 
metabolites between groups in glycolysis and citrate cycle; h differential metabolites between the groups in fatty acid biosynthesis. Values were 
showed as mean peak intensities ± SEM, *P < 0.05, **P < 0.01 and ***P < 0.001, compared with untreated (HFD) group
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file  1: Figure S2). The thetayc logarithm showed the 
gut microbiota could be divided into independent 
clusters on the basis of the community composition 
(Additional file  1: Figure S3A, S3B), and the relative 
abundance of bacterial class also showed clearly dis-
tinct (Additional file  1: Figure S3C, S3D). PCoA and 
NMDS were applied to visualize the similarities or dis-
similarities of these data (Additional file 1: Figure S4). 
The weighted and unweighted unifrac significance test 
demonstrated that the microbiota structure of the BC 
treated group was distinct from that of the untreated 
group (Additional file 1: Table S5).
We detected 8272 OTUs through the three groups. By 
plotting the ranked abundance of all 8272 OTUs accord-
ing to their occurrence, we chose the highest 50 OTUs 
in species abundance, most of which distributed across 
such families as Bacteroidaceae (12 OTUs), S24-7 (5 
OTUs), Enterobacteriaceae (5 OTUs), Prevotellaceae (5 
OTUs), Ruminococcaceae (4 OTUs), Paraprevotellaceae 
(4 OTUs), Lachnospiraceae (3 OTUs), Desulfovibrion-
aceae (2 OTUs), Verrucomicrobiaceae (2 OTUs) and 
Lachnospiraceae (2 OTUs). According to frequency 
within each sample, the heat map showed the genus level 
clustering (Fig. 6a), 31 of the 50 identified key OTUs were 
eliminated or decreased in HFD group, namely Bacte-
roides (3 OTUs), Prevotella (4 OTUs) and one OTU to 
each of the following genera: Escherichia, Sutterella, 
Parabacteroides, Clostridium and Blautia. Meanwhile, 
hyperlipidemic rats showed higher abundance of Akker-
mansia. 27 of the 50 identified key OTUs were eliminated 
or decreased with BC intervention, whereas the rest of 
identified OTUs were enriched. The identified OTUs 
belonging to Prevotella (4 OTUs) and one OTU to each 
of the following genera: Escherichia, Clostridium and 
Sutterella, which were markedly decreased at genus level 
in the BC treated group. Meanwhile, higher abundances 
Fig. 3 The metabolic profiles in the urine. The HFD induced hyperlipidemic rats were treated with or without BC for 4-week, urine was collected, 
and metabolomics analysis was made by GC/MS. a PCA score plots of urine samples from BC treated group and untreated group; b scores plots of 
OPLS-DA between untreated group and BC treated group; c Pearson’s correlations of the quantities of the 35 metabolites determined from rat urine 
samples; d heat map showing the FC of 19 metabolites. Shades of blue represent FC decrease while red represent FC increase; e simplified draft 
illustrating perturbed pathways involved; f differential metabolites between groups in vitamin B6 metabolism; g differential metabolites between 
groups in phenylalanine metabolism. Values were showed as mean peak intensities ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001, compared with 
untreated (HFD) group
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of Bacteroides (10 OTUs), Parabacteroides (1 OTU) and 
Blautia (1 OTU) were observed in the BC treated group 
(Fig. 6b).
The safety parameters of BC in serum
Analysis of serum ALT and AST showed that HFD-fed 
rats exhibited increase in these liver enzymes, suggest-
ing compromised liver function was associated with 
hyperlipidemia (Table  2). However TBIL or TBA in the 
hyperlipidemic rats were normal (Table  2). Treatment 
with BC normalized serum AST to control level, and also 
had a trend in reducing ALT in the hyperlipidemic rats 
(Table 2). Overall, the BC treatment showed no adverse 
effect on any of the parameters examined (Table 2), sug-
gesting the dosage of BC was well tolerated in these ani-
mals. The food intake and body weight gain were not 
affected by the BC treatment (Table 1), nor was dry stool 
or diarrhea observed in BC treated rats (data not shown).
Discussion
Hyperlipidemia is one of the components of metabolic 
syndrome, the pathophysiology is very complex and has 
been only partially elucidated. Insulin resistance and 
obesity are implicated in the development of hyper-
lipidemia, however, there is debate regarding whether 
they are the cause or the consequences of a more 
far-reaching metabolic derangement. It is generally 
accepted that the current food environment is the con-
tributor. For the treatment of hyperlipidemia, dietary 
modification is the initial approach, but many patients 
require pharmacological therapy to reduce cardiovas-
cular risk. The most commonly used agents are statins 
(3-hydroxy-3-methyl glutaryl coenzyme A reductase 
inhibitors) and fibrates (peroxisome proliferator-acti-
vated receptor-alpha agonists), these agents, while 
effective, cause a markedly increased risk of myopathy 
and rhabdomyolysis [5].
Fig. 4 The metabolic profiles in liver tissue. The HFD induced hyperlipidemic rats were treated with or without BC for 4-week, liver tissues were 
collected, and metabolomics analysis was made by GC/MS. a PCA score plots of liver samples from BC treated group and untreated group; b scores 
plots of OPLS-DA between untreated group and BC treated group; c Pearson’s correlations of the quantities of the 13 metabolites determined from 
rat liver samples; d heat map showing the FC of 19 metabolites. Shades of green represent FC decrease while red represent FC increase; e simplified 
draft illustrating perturbed pathways involved; f differential metabolites between groups in the liver. Values were showed as mean peak intensities 
± SEM. *P < 0.05; **P < 0.01, compared with untreated (HFD) group
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The ingredients of BC were all derived from natu-
ral plants and dietary supplements, unless overdose, the 
safety can be guaranteed. BBR is the main ingredient of 
BC, and many studies have shown the multiple molecu-
lar mechanisms and pathways underlying the beneficial 
effects of BBR in metabolic diseases. Main targets of BBR 
on lipid and glucose metabolism are low-density lipopro-
tein receptor (LDLR) and the insulin receptor (InsR), and 
this one-drug-multiple-target characteristic is required for 
the treatment of hyperlipidemia. We added oryzanol and 
vitamin B6 at a dose much lower than the tolerable upper 
intake level, and studies have confirmed their benefits on 
metabolic diseases, however, with a much higher dosage 
(oryzanol at 3.2  g/kg, vitamin B6 at 50  mg/kg) [13, 24]. 
The current study confirmed the significant lipid-lowering 
effect of BC and did not detect any evidence for side effects 
with the 4-week BC intervention. These results were con-
sistent with the data obtained in BBR studies [25].
By applying integrated metabolomics in serum, urine, 
liver and feces, we identified a number of metabolites 
in the hyperlipidemic rats treated with BC. The most 
obvious finding of our GC/MS analysis was the metabo-
lites related to lipid metabolism. Blood lipids, derived 
from food intake or adipose tissue and liver, are mainly 
fatty acid derivatives and cholesterol [26]. Besides bio-
chemistry evidence of lipid-lowering activity, BC also 
Fig. 5 The metabolic profiles in feces. The HFD induced hyperlipidemic rats were treated with or without BC for 4-week, feces were collected, and 
metabolomics analysis was made by GC/MS. a PCA score plots of the feces from BC treated group and untreated group; b scores plots of PLS-DA 
between untreated group and BC treated group; c Pearson’s correlations of the quantities of the 67 metabolites determined from the feces samples; 
d heat map showing the FC of 19 metabolites, shades of green represent FC decrease while red represent FC increase; e simplified draft illustrating 
perturbed pathways involved; f differential metabolites between the groups in tyrosine metabolism; g differential metabolites between the groups 
in β-alanine metabolism; h differential metabolites between the groups in arginine and proline metabolism; i differential metabolites between the 
groups in secondary bile acid biosynthesis. Values were showed as mean peak intensities ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001, compared 
with untreated (HFD) group
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affected the lipid metabolism related metabolites. FFAs 
are catabolized in the mitochondria to produce energy, 
and the process generated numerous metabolites [27]. 
The change of serum metabolites suggested an attenu-
ated fatty acids synthesis pathway and an enhanced 
β-oxidation pathway in BC treated hyperlipidemic rats.
Putrescine is a polyamine that is important for cell 
functions, polyamine can participate in fatty acid metab-
olism by spermidine/spermine N1-acetyltransferase 
(SSAT), and enhanced ornithine decarboxylase (ODC) 
and SSAT activities may promote acetyl-CoA conversion 
from fatty acid synthesis to acetylation of polyamines. In 
other words, increase of putrescine indicates enhanced 
fatty acid β-oxidation [28].
Another important finding was the metabolites related 
to glycolysis and the TCA cycle. HFD-induced hyperlipi-
demic rats demonstrated glycolysis inhibition and energy 
metabolism dysfunction, and BC were found to restore 
this status by up-regulating the level of glucose, pyru-
vate, glucose-6-phosphate, oxaloacetic acid and succinate 
among others. Pyruvate, a key metabolite linking gly-
colysis to the TCA cycle, are derived from glycolysis and 
can be used to produce acetyl-CoA, then enters into the 
TCA cycle [17]. Hyperlipidemia generates large amount 
of acetyl-CoA, which would inhibit pyruvate conver-
sion in a negative feedback way [29]. Our results are in 
line with previous study that shows similar alterations in 
glucose and energy metabolism [30], indicating BC treat-
ment affected glycolysis process and the TCA cycle by 
recovering the suppressed energy metabolism. However, 
the scope of this study was limited in terms of glucose 
metabolism, since blood glucose levels did not increase 
in response to the dietary, thus the effect of BC treatment 
on hyperglycemia was unable to determine.
The levels of the gluconeogenic amino acids (e.g. ala-
nine, valine, threonine, glutamine, serine, glycine, aspar-
tate, proline) as well as those of the ketogenic amino 
acids (e.g. isoleucine, lysine, tyrosine, phenylalanine, 
Fig. 6 The structure of micorbiota in the feces. Heat map of key OTUs indicating genus-level changes among the groups. The relative abundance of 
each genus was indicated by a gradient of color from green (low abundance) to red (high abundance). Complete linkage clustering of samples was 
based on the genus composition and abundance. a Chow group versus HFD group; b BC treated (HFD) group versus untreated group
Table 2 Serum biochemical parameters related to  BC 
safety
Data are presented as Mean ± SD
* P < 0.05, *** P < 0.001 compared with chow diet group; #  P < 0.05, compared 
with HFD group
Items Chow diet rats 
(n = 10)
HFD rats (n = 10) BC treated rats 
(n = 10)
ALT 20.3 ± 2.8 42.2 ± 12.6*** 38.0 ± 13.4***
AST 109.2 ± 6.6 151.2 ± 41.1* 107.3 ± 13.4#
TBIL 0.7 ± 0.1 0.6 ± 0.5 0.6 ± 0.2
TBA 4.5 ± 1.4 5.4 ± 1.9 7.1 ± 3.4
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tryptophan) were increased upon BC treatment. Pheny-
lalanine and tyrosine are the precursor of epinephrine, 
and tyrosine consumption increases when epinephrine 
is in demand for lipid metabolism [31]. BC administra-
tion caused tyrosine level decrease in our study, impli-
cating that the epinephrine pathway might be involved. 
The glutathione precursor, glutamate is the first line of 
defense against free radicals in the liver, and is an essen-
tial amino acid during the pathogenesis of metabolic dis-
eases [32]. Although the increase of hepatic glutamate in 
our study was not statistically significant, the glutamate 
level in both urine and feces markedly decreased, indi-
cating the reduced degradation and secretion of glu-
tamate. This finding demonstrated that anti-oxidative 
activity is one of the possible properties of the BC, and it 
seemed to be in agreement of the results obtained from 
gallic acid studies [33]. The branched chain amino acids 
(BCAAs: leucine, isoleucine, and valine) play impor-
tant roles in promoting protein synthesis [34], glucose 
metabolism and oxidation [35], and regulating leptin 
secretion [36]. High levels of BCAAs contribute to obe-
sity-related insulin resistance and glucose intolerance 
[37], and a recent study has reported that the blood con-
centration of five branched-chain and aromatic amino 
acids (isoleucine, leucine, valine, tyrosine, and phenyla-
lanine) could predict the risk of future diabetes [38]. BC 
were found to have certain actions on the metabolites 
of BCAAs, which might be contribute to ketogenesis 
suppression.
Vitamin B6 consists of pyridoxal, pyridoxine, and pyri-
doxamine, which functions as essential cofactors for 
enzymes involved in various metabolic activities [39]. The 
biologically active form is the phosphate ester derivative 
pyridoxal 5′-phosphate (PLP), which could reflect long-
term body storage [40]. Low plasma PLP is the marker of 
diminished vitamin B6 that adversely affects polyunsatu-
rated fatty acid metabolism, arachidonic acid and hepatic 
cholesterol biosynthesis. An increase in pyridoxine and 
4-pyridoxic acid was present in BC treated rats, suggest-
ing an enhanced vitamin B6 metabolism.
Interestingly, the production of fecal secondary bile 
acids, deoxycholate (DCA) and lithocholate (LCA), 
which are synthesized from primary bile acids cho-
late and chenodeoxycholate by a few species of intesti-
nal bacteria, respectively [41], were markedly reduced 
in BC treatment group. LCA, the most toxic bile acid 
[42], could induce DNA damage and inhibit DNA repair 
enzymes [43]. Recently, it has been reported that dietary 
vitamin B6 could reduce the production of LCA in HFD 
rats. These findings implied vitamin B6 may be beneficial 
for intestine health under HFD conditions [44].
Recent studies have shown the diversity and composi-
tion of gut microbiome altered in metabolic diseases. 
Bacteroides is negatively correlated with energy intake 
and obesity [45]. Blautia is an acetogen belongs to the 
known SCFA-producing bacteria. Abundance of the 
SCFA producer helps to alleviate systemic inflammation 
by promoting energy intake and elevating intestinal SCFA 
levels. Our study suggests that structural modulation of 
gut microbiota was in response to BC intervention, and 
these changes might contribute to the enhancement of 
energy metabolism.
As mentioned, BBR causes side effects related to its 
impact on bowel motility including abdominal pain, dis-
tention, nausea, vomiting, and constipation [46]. During 
the process of our experiment, no obvious gastrointes-
tinal symptom was observed in the BC treated rats. The 
significant increase in serotonin and putrescine are 
intriguing. Serotonin mediates effects not only on sleep, 
emotion and appetite but also on neural reflexes that reg-
ulate gastrointestinal motility, secretion, and sensation 
[47]. Putrescine, synthesized from ornithine by ODC, 
may be an important substance with respect to intesti-
nal function as it is an instant energy source in times of 
energy deficiency in gut metabolism [48]. The increases 
in serotonin and putrescine may therefore imply BC 
could reduce gastrointestinal discomfort discovered 
in previous BBR research by regulating colonic motor 
activity.
Conclusions
The present study determined the anti-hyperlipidemia 
effect of BC on diet-induced hyperlipidemic rats. Accord-
ing to the alterations in metabolites from different types 
of sample and gut microbiota structure, BC were inferred 
to partially recover both metabolism dysfunction and 
intestinal environment through several metabolic path-
ways (glycolysis and TCA cycle, β-oxidation of fatty 
acids, synthesis of fatty acid and cholesterol, amino acid 
metabolism, vitamin B6 metabolism, and secondary bile 
acid biosynthesis) and modulation of the micorbiota. 
What’s more, these findings imply the possibility of BC 
treatment on improving the gastrointestinal discomfort. 
This research provided a framework for the exploration 
of natural products on metabolic diseases in holistic and 
systematic manners. Further researches are required to 
optimize the specialized targets of BC and establish a 
comprehensive screening system for hyperlipidemia.
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